Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
about
Anti-endotoxin vaccines: back to the futurePreparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugatesSafety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsisIntranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cellsEstimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection.Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.Immunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid.Pseudomonas aeruginosa PAO-1 Lipopolysaccharide-Diphtheria Toxoid Conjugate Vaccine: Preparation, Characterization and ImmunogenicityPseudomonas aeruginosa: the potential to immunise against infection.Synthesis, characterization and immunological properties of Escherichia coli 0157:H7 lipopolysaccharide- diphtheria toxoid conjugate vaccine.Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsisPolysaccharide antigens of Pseudomonas aeruginosa.Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residueIsolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharidesRecent developments for Pseudomonas vaccines.Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.Potential targets for next generation anti-microbial glycoconjugate vaccines.
P2860
Q22305428-CBE0D4D0-9354-4720-A300-20DC996F3306Q33595722-5430A915-26C7-4536-85C7-8DF1B2CB414AQ34000731-2FC916C9-C572-4793-AD53-5E99AEFE646EQ34006764-7061C236-FF3C-4BE9-A45F-B508FB6D9118Q34111774-240384EC-1E91-4822-82DC-493F1A8686FFQ34526632-848014D6-CB13-475E-9378-F3C418A22886Q34532344-DC8734B7-8E67-4DFB-91C1-A1D760863680Q35090330-5BCC01A6-01BE-4668-88EB-651675387EFFQ35206982-A9CA1801-7E39-4B0D-90AA-85DB44B7A986Q35270721-A8D5E154-F219-42F5-AE3D-E09B74FF3653Q35969060-6FB7351D-684A-43FB-80A1-27FB20F9E9C9Q36194089-4C2DC6C0-68AB-4E27-A027-C7C2327DF79CQ36366407-990E61BC-4E29-4A1E-A243-DE46A113F7BDQ36372619-A40EE774-C4E0-496F-98FE-42A199A3E6E0Q36597493-38970550-243A-410C-9517-E26495B9F7C4Q36976544-D68A6292-53A1-48B0-8C42-45D919B506D2Q36989971-548476FF-1831-4A23-9566-F60FA0255B34Q37001754-C381F432-6F2A-4E7D-8BC2-93DAAEB786A3Q37007144-E30CA844-9356-4212-A770-EA13AB5E6E9DQ37937369-1770B20F-F9DA-490E-B2E5-54CCED1CABD7Q40149473-B937B7CA-8423-4EBA-9CFF-5E94B53C0BE4Q40158359-81162AE8-1741-4C02-A74B-91A947578A41Q40159003-9104BD50-AD2F-4A8B-B331-22AD9A943DF9Q53701548-E262C466-428C-41C9-A5D4-DD8D5EA149A8
P2860
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@ast
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@en
type
label
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@ast
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@en
prefLabel
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@ast
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@en
P2093
P2860
P356
P1476
Safety and immunogenicity of a ...... A conjugate vaccine in humans.
@en
P2093
P2860
P356
10.1172/JCI113062
P407
P577
1987-07-01T00:00:00Z